Prevalence of COVID-19 Antibodies Kingman AZ
Study Details
Study Description
Brief Summary
The COVID-19 disease outbreak is a historic event that has challenged medical systems in the United States. Currently, most reports of confirmed cases rely on the testing of symptomatic patients. These estimates of confirmed cases miss individuals who have recovered from infection, with mild or no symptoms, and individuals with symptoms who have not been tested due to the limited availability of tests. We are conducting serology testing within the community for SARS-CoV-2-specific antibodies through a serologic test could give insight into past COVID-19 infections within our community.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Adult participants aged 18 or greater will be recruited from the greater Kingman AZ area through social media, radio, newspaper, and a press release. Participants self-selected inclusion in the study by calling into a COVID-19 hotline and will be included in the sample data following self-report of absence of covid-19 symptoms. Participants will be scheduled for testing on the weeks of 09/28/2020 and 10/05/2020. Upon recruitment, participants will be asked to complete a demographic and behavioral survey, assessing socioeconomic status, interpersonal interactions, personal protective measures, and COVID-19 symptomology in the preceding two months. Two months after initial testing, all negative SARS-CoV-2-specific antibodies participants will be contacted for repeat testing and surveying.
SARS-CoV-2-specific antibodies will be tested using a lateral flow immunoassay with the VITROS Anti-SARS-CoV-2 IgG test (Ortho-Clinical Diagnostics, Inc.) under the Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA). The diagnostic sensitivity of the immunoassay was 87.5% and specificity was 100%. The positive and negative predictive value with a prevalence of 5% in the community was 100% and 99.3% respectively. All data will be de-identified and stored in a password protected file only visible to study investigators. All positive results were called back to participants by the lead author.
Data obtained was then used to estimate the population prevalence of SARS-CoV-2-specific antibodies in the Kingman, Arizona population. Unweighted and weighted proportions of positive tests were calculated to match the 2018 census on sex, race, education, and income. Confidence intervals for unweighted data will be estimated using exact binomial models and for weighted and adjusted estimates using bootstrap methods. All data was analyzed using SPSS.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Community Cohort 1 1000 Participants from the community will be recruited to undergo serological testing for SARS-CoV2 Antibodies at time point 1. |
Diagnostic Test: VITROS Anti-SARS-CoV-2 IgG test
The VITROS Anti-SARS-CoV-2 IgG test is a lateral flow immunoassay produced by Ortho-Clinical Diagnostics Inc.
|
| Community Cohort 2 1000 Participants from the community will be recruited to undergo serological testing for SARS-CoV2 Antibodies at time point 2. |
Diagnostic Test: VITROS Anti-SARS-CoV-2 IgG test
The VITROS Anti-SARS-CoV-2 IgG test is a lateral flow immunoassay produced by Ortho-Clinical Diagnostics Inc.
|
| Healthcare Provider Cohort 1 500 hospital employees will be recruited to undergo serological testing for SARS-CoV2 Antibodies at time point 1. |
Diagnostic Test: VITROS Anti-SARS-CoV-2 IgG test
The VITROS Anti-SARS-CoV-2 IgG test is a lateral flow immunoassay produced by Ortho-Clinical Diagnostics Inc.
|
| Healthcare Provider Cohort 2 500 hospital employees will be recruited to undergo serological testing for SARS-CoV2 Antibodies at time point 2. |
Diagnostic Test: VITROS Anti-SARS-CoV-2 IgG test
The VITROS Anti-SARS-CoV-2 IgG test is a lateral flow immunoassay produced by Ortho-Clinical Diagnostics Inc.
|
Outcome Measures
Primary Outcome Measures
- Seroprevelence of SARS-CoV-2 Antibodies among Adults in Kingman AZ [2-weeks]
A sample from the population of Kingman AZ will be used to determine the epidemiology of COVID-19 spread throughout Kingman AZ.
Secondary Outcome Measures
- Retention of SARS-CoV-2 Antibodies among Adults in Kingman AZ [2-weeks]
Participants will have a second antibody diagnostic test 2 months following initial enrollment. The concordance between positive tests will then be used to determine the longevity of SARS-CoV-2 antibodies in our community.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Adults aged 18+
-
Resident of Mohave County AZ
Exclusion Criteria:
-
Children under 18yo
-
Previous positive SARS-CoV2- Antibody Test
-
Active symptoms of respiratory Illness
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Kingman Regional Medical Center | Kingman | Arizona | United States | 86409 |
Sponsors and Collaborators
- Kingman Regional Medical Center
Investigators
- Study Director: Anthony J Santarelli, PhD, Kingman Healthcare Inc.
Study Documents (Full-Text)
None provided.More Information
Publications
- Paul R, Arif AA, Adeyemi O, Ghosh S, Han D. Progression of COVID-19 From Urban to Rural Areas in the United States: A Spatiotemporal Analysis of Prevalence Rates. J Rural Health. 2020 Sep;36(4):591-601. doi: 10.1111/jrh.12486. Epub 2020 Jun 30.
- Peters DJ. Community Susceptibility and Resiliency to COVID-19 Across the Rural-Urban Continuum in the United States. J Rural Health. 2020 Jun;36(3):446-456. doi: 10.1111/jrh.12477. Epub 2020 Jun 16.
- KRMC 0205